Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The new partnership between Oxford Health NHS Foundation Trust, the University of Oxford, the University of Toronto, and the Centre for Addiction and Mental Health (CAMH) in Toronto, will enable the development of key structures to facilitate collaboration.

Under the terms of the agreement, the partners plan to:

  • Share clinical and research science expertise, capacity building and access to industry
  • Collaborate on digital innovation programmes
  • Collaborate on staff and student exchange programmes
  • Co-host symposia, conferences, seminars and other events
  • Make joint applications for funding

Digital healthcare will be one of the first areas of focus. The group will support global research cooperation and work to attract greater international recognition for mental health research.

Professor John Geddes, Head of the Department of Psychiatry, University of Oxford, and Director of the Oxford Health Biomedical Research Centre, said:

'International collaboration is crucial for developing both research and clinical practice. Signing the Memorandum of Understanding with out partners in Canada will enable us to promote a culture of collaboration and data science in mental health and build new networks to meet the needs of 21st century mental health research. The benefits of this agreement will be shared across research organisations and healthcare providers not only in North America and Europe, but also globally.'

The signing of a Memorandum of Understanding between the four organisations took place in March 2021.

To read the full story.

Similar stories

New European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.

Experimental Medicine and Industry Partnership

The recent launch event of the Experimental Medicine Industry Partnership was an exciting collaboration between industry representatives and researchers from the University of Oxford. During the event, a series of workshops were held to discuss opportunities, challenges, and future directions for the application of experimental medicine in psychiatric drug development.

Major research network to investigate body clock and stroke

The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.

Mapping uncharted networks in the progression of Parkinson’s

A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between a core team of Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institute, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.